Catalent Pharma Solutions and Toyobo Biologics, Inc. (TBI) have entered into a partnership agreement to co-promote Catalent’s proprietary GPEx technology in the Japanese market. TBI is a biologics supplier and contract provider of large scale clinical and commercial bioreactors in Japan. GPEx technology is used for mammalian cell line development. It creates stable, high expression cell lines “that will speed biologics drug development to clinic in one-third the time of traditional approa...